BACKGROUND: Weight modification after a diagnosis of colon cancer and its impact on outcomes remain unclear. Thus we aimed to examine the association of obesity and weight changes from baseline oncology consultation with recurrence-free survival (RFS) and overall survival (OS) in patients with stage III colon cancer. METHODS: Patients aged ≥ 18 years who were diagnosed with stage III colon cancer in British Columbia from 2008 to 2010 and who received adjuvant chemotherapy were included in the study. Cox proportional hazards regression models were fitted to evaluate the impact of different body compositions and degree of weight changes from baseline assessment with outcomes while controlling for potentially confounding covariates, such as age and sex. RESULTS: A total of 539 patients with stage III colon cancer were included: median age was 69 years (range, 26-94 years), 52% were men, and 53% had Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Those with weight gains of ≥ 10% had a median RFS of 37 months compared with 49 months in those with weight gains of < 10% (hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.56-1.59; P = .82). However, this finding was not significant. In Cox models, patients who exhibited weight losses of ≥ 10% experienced significantly inferior RFS (HR, 3.45; 95% CI, 1.44-8.13; P = .0046) and OS (HR, 2.63; 95% CI, 1.04-6.67; P = .041) compared with those who experienced weight losses of < 10%. Weight gains, losses, or changes of equal or less magnitude did not show any significant associations with outcomes (all P > .05). CONCLUSIONS: Weight losses of ≥ 10% from baseline evaluation bodes a worse prognosis among patients with stage III colon cancer.
BACKGROUND: Weight modification after a diagnosis of colon cancer and its impact on outcomes remain unclear. Thus we aimed to examine the association of obesity and weight changes from baseline oncology consultation with recurrence-free survival (RFS) and overall survival (OS) in patients with stage III colon cancer. METHODS:Patients aged ≥ 18 years who were diagnosed with stage III colon cancer in British Columbia from 2008 to 2010 and who received adjuvant chemotherapy were included in the study. Cox proportional hazards regression models were fitted to evaluate the impact of different body compositions and degree of weight changes from baseline assessment with outcomes while controlling for potentially confounding covariates, such as age and sex. RESULTS: A total of 539 patients with stage III colon cancer were included: median age was 69 years (range, 26-94 years), 52% were men, and 53% had Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Those with weight gains of ≥ 10% had a median RFS of 37 months compared with 49 months in those with weight gains of < 10% (hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.56-1.59; P = .82). However, this finding was not significant. In Cox models, patients who exhibited weight losses of ≥ 10% experienced significantly inferior RFS (HR, 3.45; 95% CI, 1.44-8.13; P = .0046) and OS (HR, 2.63; 95% CI, 1.04-6.67; P = .041) compared with those who experienced weight losses of < 10%. Weight gains, losses, or changes of equal or less magnitude did not show any significant associations with outcomes (all P > .05). CONCLUSIONS: Weight losses of ≥ 10% from baseline evaluation bodes a worse prognosis among patients with stage III colon cancer.
Authors: Jonathan M Kocarnik; Xinwei Hua; Sheetal Hardikar; Jamaica Robinson; Noralane M Lindor; Aung Ko Win; John L Hopper; Jane C Figueiredo; John D Potter; Peter T Campbell; Steven Gallinger; Michelle Cotterchio; Scott V Adams; Stacey A Cohen; Amanda I Phipps; Polly A Newcomb Journal: Cancer Date: 2017-08-25 Impact factor: 6.860
Authors: Moniek van Zutphen; Hendriek C Boshuizen; Dieuwertje E Kok; Harm van Baar; Anne J M R Geijsen; Evertine Wesselink; Renate M Winkels; Henk K van Halteren; Johannes H W de Wilt; Ellen Kampman; Fränzel J B van Duijnhoven Journal: J Cancer Surviv Date: 2019-10-23 Impact factor: 4.442
Authors: Brendan J Guercio; Sui Zhang; Alan P Venook; Fang-Shu Ou; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Brian C Mullen; Bert H O'Neil; James E Shaw; Blase N Polite; Howard S Hochster; James N Atkins; Richard M Goldberg; Justin C Brown; Eileen M O'Reilly; Robert J Mayer; Charles D Blanke; Charles S Fuchs; Jeffrey A Meyerhardt Journal: JNCI Cancer Spectr Date: 2020-03-31
Authors: Justin C Brown; Bette J Caan; Jeffrey A Meyerhardt; Erin Weltzien; Jingjie Xiao; Elizabeth M Cespedes Feliciano; Candyce H Kroenke; Adrienne Castillo; Marilyn L Kwan; Carla M Prado Journal: J Cachexia Sarcopenia Muscle Date: 2018-05-15 Impact factor: 12.910
Authors: Moniek van Zutphen; Anouk Geelen; Hendriek C Boshuizen; Renate M Winkels; Anne J M R Geijsen; Evertine Wesselink; Merel Snellen; Dieuwertje E Kok; Johannes H W de Wilt; Paul C van de Meeberg; Ewout A Kouwenhoven; Henk K van Halteren; Ernst J Spillenaar Bilgen; Ellen Kampman; Fränzel J B van Duijnhoven Journal: Support Care Cancer Date: 2018-11-27 Impact factor: 3.603